logo-loader

EMV Capital's numbers cleaned up as portfolio spin-outs remove the noise

Published: 00:01 25 Sep 2026 AEST

EMV Capital - EMV Capital's numbers cleaned up as portfolio spin-outs remove the noise

Panmure Liberum has trimmed its price target on EMV Capital (AIM:EMVC, FRA:NTK1) to 128p from 132p, but stuck with a "buy" call, arguing that a pair of portfolio spin-outs will leave the growth capital investor's accounts far easier to read.

The broker sees more than 160% upside from the current 48.5p, with the shares trading at a roughly 57% discount to its estimated sum-of-the-parts valuation.

EMV Capital (AIM:EMVC), which manages funds and takes stakes in early-stage, science-based companies, saw group revenue rise about 22% in the first half, with core revenue up 9% to £1.5 million.

The headline figures were distorted by the deconsolidation of two holdings, Glycotest and ProAxsis, after both raised money from outside investors and ceased to be subsidiaries.

That change generated a £25.1 million non-cash gain, flipping the group to a reported profit of about £18.4 million and lifting net asset value per share 150% to around 122p.

Analyst Callum Stokeld said the shuffle means future reported numbers should give a cleaner picture of the underlying business, a fund and investment management platform with recurring fee income alongside a portfolio of directly held stakes.

He flagged several potential triggers for value uplift across the portfolio of more than 70 companies, including clinical data from Glycotest due late this year.

Panmure also pointed to a post-period deal to buy the Pryme plastic waste recycling plant, funded entirely by third-party debt, as evidence the structure lets management move quickly.

Assets under management rose 4% to £117.5 million.

XanaMIA results: What's next for Actinogen Medical?

Actinogen Medical Ltd CEO Dr Steven Gourlay talked with Proactive about the topline results from the company's XanaMIA clinical trial, which evaluated its investigational Alzheimer's disease treatment Xanamem. The study revealed encouraging signs of disease slowing in patients aged...

10 hours, 18 minutes ago